Find Clinical Trials

Inclusion Criteria: * Having a diagnosis of Familial Mediterranean Fever * Being literate * Being 18 years of age or older * Having read and signed the informed consent Exclusion Criteria: * History of major psychiatric illness * Malignant disease * History of peripheral vascular disease or neuropathy * Not volunteering for the study

Inclusion Criteria: * Having been diagnosed with T2DM, * Being between the ages of 40-65, * Being able to walk independently, * Being willing to exercise at least 2 days a week in the intervention groups as required by the research, * Not having cooperation and communication problems, * Not having participated in a regular exercise program in the last 6 months. Exclusion Criteria: * Patients who do not volunteer to participate in the study * Patients with complications such as diabetes-related nephropathy, neuropathy, retinopathy * Patients with orthopedic, neurological, surgical problems that prevent them from walking and exercising * Patients with cardiac, pulmonary, or systemic diseases that prevent them from exercising * Patients with vision problems that cannot be corrected with glasses or lenses * Patients with hearing loss that cannot be corrected with hearing aids

Inclusion Criteria: * 18-59 years old * Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) * Confirmed HIV diagnosis * Current receipt of daily oral antiretroviral therapy (ART) medication * English fluency/literacy Exclusion Criteria: * Acute brain infection (e.g., neurosyphilis, toxoplasmosis) * Acutely symptomatic bipolar I or psychotic disorder * Prescription for immunomodulatory medications or other immunotherapy * Any MRI contraindications * If applicable, on antidepressant medication regimen for at least 2 months

Inclusion Criteria: * Having diabetes for at least 6 months * Being over 18 years old * To have sufficient communication skills to answer verbal and written questions and fulfill instructions * Being literate * No physical, cognitive or mental impairment in answering the questions * Willingness to participate in research. Exclusion Criteria: * Being under 18 years of age * Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process * The emergence of any health problem that prevents the person from continuing the research * Do not leave the study voluntarily.

Inclusion Criteria : \- Individuals older than 18 with an elevated office blood pressure : * suspected hypertension diagnosis or * uncontrolled hypertension under treatment Exclusion Criteria: 24-hour ABPM recordings presenting: * less than 70% of the expected measurements or * fewer than 20 valid awake or seven valid sleeping measurements or * fewer than two valid daytime and one valid night-time measurement per hour

Inclusion Criteria: * Age ≥18 years * Histologic confirmation of breast cancer from 1/1/2022 * Patient treated with systemic and surgical therapy (retrospective phase) * Signed informed consent * HER2-0 and/or HER2-low patient, according to IHC and D-DISH/FISH, treatable with systemic and surgical therapy (prospective phase) Exclusion Criteria: * Lack of molecular classification on the basis of prognostic-predictive markers ER, PR, Ki67 and HER2 (Luminal A, Luminal B HER2-positive, Luminal B HER2- negative, HER2-positive, Triple negative) * Prior neoplasms, other than the neoplasm under investigation, arised within the past 5 years * Missing histological diagnosis of HER2-0 and/or HER2-low breast cancer (prospective phase)

Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified): * Have pathologically documented BC that: * Is locally advanced, unresectable or metastatic. * Has a confirmed HER2 status as determined by the local laboratory as standard of care testing prior to study screening (Part 1, Part 2 Cohorts 2 and 4) or the central laboratory (Part 2, Cohorts 1 and 3) from the most recently collected pre-randomization tumor sample. * Has a documented history of HER2 expression consistent with the subgroup definitions (i.e., HER2-low, HER2-ultralow, HER2-null, HER2-positive, or TNBC) as per current American Society of Clinical Oncology/College of American Pathologists guidelines. * Have measurable disease defined by RECIST v1.1. * Has left ventricular ejection fraction ≥55% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment. Key Exclusion Criteria: * Have history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP. * Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse events. * Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment. * Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Had prior treatment with topoisomerase I inhibitors, including antibody-drug conjugates with topoisomerase I inhibitor payloads such as trastuzumab deruxtecan. * Have received any of the following therapies or drugs prior to the initiation of the study: * Participants who have received prior treatment with BNT323. * Participants who received prior treatment with a programmed death-ligand 1 (PD-L1) / vascular endothelial growth factor (VEGF) bispecific antibody. Note: Prior treatment with programmed death 1 (PD-1)/VEGF bispecific antibodies, PD-1/PD-L1 inhibitors or anti-VEGF therapies are permitted. * Have received other systemic immunostimulatory agents or immunosuppressive therapies (such as interferon-α, interleukin-2, or methotrexate) within 4 weeks prior to the initiation of study treatment or are within five half-lives of the treatment drug (whichever is longer). Exception: excluding local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens). * Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 3 weeks prior to the initiation of study treatment. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Inclusion Criteria: 1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment. 2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment. 3. 7.0% ≤ HbA1c \< 10.0% based on laboratory tests performed within 4 weeks of enrollment. 4. Voluntarily give written informed consent after being told about the study. Exclusion Criteria: 1. Patients with type 1 diabetes and secondary diabetes. 2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment. 3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study. 4. End-stage renal disease and hemodialysis patients. 5. diabetic ketoacidosis Patients. 6. Pregnant and lactating women. 7. Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice. 8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients. 9. Anyone else deemed by the investigator to be unsuitable for participation in the study.

Inclusion into the study will not depend on sex, ethnicity, or race. We will monitor enrollment to ensure a diversity of sex and race/ethnicity are represented. PARENT-CHILD PAIR INCLUSION CRITERIA 1. Caregivers must be at least 18 years old (defined as parent or legal guardian) 2. The child (patient) has a diagnosis of asthma associated with a clinic visit in the electronic health record 3. The child is between the ages of 4-17 years old at the time of recruitment 1. The study is interested in the self-management of asthma by caregivers, whom are still primarily responsible for their child's chronic disease management. 2. Children younger than 4 years old will not be included in this study as the diagnosis of asthma is typically difficult to confirm in younger ages. 4. The child is prescribed inhaled corticosteroid or corticosteroid/long-acting beta agonist combination for daily use. The patient can have an inhaled corticosteroid/long-acting beta agonist for both daily preventive and rescue use, as in Single Maintenance and Reliever Therapy (SMART). 5. Persistent or un controlled asthma based on NHLBI guidelines40; Any 1 of the following: 1. In past month, \>2 days per week with asthma symptoms 2. \>2 days per week with rescue medication use 3. \>2 days per month with nighttime awakenings (for children who are not taking a controller asthma medication) OR \>2 days per month with nighttime awakenings (for children who are currently taking a controller asthma medication) 4. \>2 asthma episodes during the past year that required systemic corticosteroids 6. The child is a patient in Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH PARENT-CHILD PAIR EXCLUSION CRITERIA 1. The caregiver has a smartphone that is not compatible with the Hailie® app. 2. The patient is prescribed a controller (preventive) or rescue inhaler medication to which the Hailie electronic sensor cannot affix. 3. The caregiver is unable to speak and understand English. a. With this trial, the intent is to first establish feasibility and broaden to different languages in future. 4. The child has clinically significant, comorbid diagnoses, such as cystic fibrosis, cyanotic heart disease, or bronchopulmonary dysplasia, that could interact with their assessment of asthma-related measures. 5. The family has active Department of Child and Family Services (DCFS) involvement 6. The participant is enrolled in another asthma intervention study at the time of enrollment to this study. 7. Child or sibling living in the same home was previously enrolled in this study. 8. Consent is not obtained from the parent/guardian. 9. Parent/guardian does not pass the test of understanding at study enrollment. HEALTH CARE PROVIDER INCLUSION CRITERIA (IMPLEMENTATION OUTCOMES) 1. Participant is an employee of LCH system 2. Works at or supports the operations of Primary Care Uptown, Primary Care Deming, Allergy, or Pulmonary Clinics at LCH 3. Able to provide informed consent HEALTH CARE PROVIDER EXCLUSION CRITERIA (IMPLEMENTATION OUTCOMES) 1\. Participant departs LCH and is no longer an active employee at the time of assessment

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has locally recurrent unresectable or metastatic TNBC that cannot be treated with curative intent * Has not received systemic treatment for locally recurrent unresectable or metastatic breast cancer * Participants previously treated for early-stage breast cancer must have completed all prior therapy for early-stage breast cancer with curative intent at least 6 months before the first disease recurrence * Is a candidate for treatment with pembrolizumab and one of the TPC options: paclitaxel or nab-paclitaxel or gemcitabine + carboplatin * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline with the exception of alopecia or vitiligo. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has breast cancer amenable to treatment with curative intent * Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10 * Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer * Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has skin only metastatic disease * Has advanced/metastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications * Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has known additional malignancy that is progressing or has required active treatment within the past 5 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable * Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments * Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (HCV) (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection * History of stem cell/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications

Inclusion Criteria: • Mild and moderate asthmatic patients aged from 6 - 80 year old. Exclusion Criteria: * Severe asthmatics or patients admitted to an intensive care unit * ischemic heart disease * recent abdominal surgery * inability to perform properly the pulmonary function tests * hepatic or renal impairment * hypersensitivity to salbutamol.

Inclusion Criteria: * Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status. * HR+ will be defined as ER and/or PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines27. Triple negative will be classified as ER and PR \<10% and HER2-. * Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+/HER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery. * Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen. To include HER2 directed therapy for HER2+ patients. * Age ≥ 18. * Life expectancy ≥ 6 months. * Eastern Cooperative Oncology Group performance status 0 to 2. * Patients must be able to understand and the willingness to sign an informed consent for study procedures. * Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: * Prior diagnosis of systemic metastases. * Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder. * Contraindication towards CT IV contrast. * Chronic kidney disease stage IV or V or end stage renal disease (CrCl \<30 ml/min).

Inclusion Criteria: * T2D * Diabetes duration of ≥12 months * ≥18 years of age * HbA1c ≥58 mmol/mol * Attending the SDCC outpatient clinic * Provided voluntary signed informed consent. Exclusion Criteria: * Inability to understand the patient information. * Complications which do not permit to lowering HbA1c to \<58 mmol/mol. * Treatment with insulin. * Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion. * Systematic use of corticosteroids. * Using or requiring a specialized diet (e.g., kidney diet). * Circumstances that affect HbA1c (e.g., liver disease and anaemia). * Known or suspected drug or alcohol abuse (judged by the investigator). * Pregnancy or breastfeeding or plans of pregnancy within the study period. * Participation in other clinical trials.

Inclusion Criteria: * Patients aged 19 years or older and under 80 years. * Patients with liver function are classified as Child-Pugh Class A. * Barcelona Clinic Liver Cancer stage C patients with no prior systemic anticancer therapy for hepatocellular carcinoma. * Patients with an Eastern Cooperative Oncology Group performance score of 0-1. * Adequate Hematologic and Liver Function: A. Hemoglobin: ≥ 9.0 g/dL B. Absolute Neutrophil Count : ≥ 1,000/mm³ C. Platelet Count: ≥ 70,000/μL D. Prothrombin Time: ≥ 70% (or Prothrombin Time INR ≤ 1.2) * Patients with upper gastrointestinal endoscopy performed within six months prior to the start of anticancer treatment. * No plans for breastfeeding, and if of childbearing potential, using contraception or no plans for spouse's pregnancy or practicing contraception. * Patients who have received an explanation of the treatment purpose and methods and have provided informed consent for the treatment. Exclusion Criteria: * Participants who have previously received systemic anticancer therapy for advanced hepatocellular carcinoma. * Patients with intrahepatic tumor involvement of 50% or more. * Patients with tumor thrombus in the main portal vein or both first-order branches (Vp4). * Patients with a prior history of liver transplantation. * with uncontrolled malignant tumors other than HCC at the time of enrollment (participation is allowed if disease-free survival exceeds two years). * Patients with uncontrolled or serious underlying diseases requiring treatment. * Patients with a history of esophageal or gastric variceal bleeding. * Previous Variceal Treatments: Patients who have undergone any of the following treatments for variceal bleeding: A. Endoscopic Variceal Obliteration (EVO) B. EVL C. Transjugular Intrahepatic Portosystemic Shunt (TIPS) D. Percutaneous Approach for Retrograde Transvenous Obliteration (PARTO) E. Surgical procedures * Patients who have used anticoagulants or antiplatelet agents within one week prior to the study. * Presence of grade 2 or higher isolated gastric varices or Red Color Signs confirmed by baseline endoscopy (EGD). * Patients who are pregnant. * Patients who are unable to understand or provide written informed consent. * Patients deemed unsuitable for clinical study participation based on the investigator's judgment.

Inclusion Criteria: 1\. Pathological diagnosis of stage I-III breast cancer (non-T4), \>18 years old; 2. Complete breast cancer resection (including skin-sparing and nipple-sparing total resection) 3. According to the guidelines of the Chinese Anticancer Society, postoperative adjuvant radiotherapy is required; 4. Undergo immediate reconstructive surgery (tissue dilator or permanent implant) Exclusion Criteria: 1. Auto-reconstruction surgery 2. Clinical or pathological T4 3. Both sides need radiotherapy 4. Have a history of chest radiotherapy 5. Pregnancy/lactation 6. Participate in other drug clinical trials

Inclusion Criteria: * Participants who require transjugular intrahepatic portosystemic shunt (TIPS) and meet the clinical indications for the procedure. * Participants whose physical condition is suitable for TIPS. Exclusion Criteria: * Participants with a history of allergy or serious adverse reactions to iodine contrast media or other related drugs. * Participants are pregnant or breastfeeding. * Participants are unwilling or unable to sign informed consent.

Inclusion Criteria: * Male and female volunteers * 18 years of age or older * Assessed for a severe asthma exacerbation * Being prescribed OCS for the management of their exacerbation * Able to comprehend and follow all required study procedures * Able to understand and give written informed consent and have signed a written informed consent form (ICF) approved by the REB Exclusion Criteria: * For females, are pregnant, or lactating * Respiratory comorbidities other than asthma, including bronchiectasis (non-CF) or asthma-COPD overlap (ACO) * FEV1 \<40% of personal best or \<1 Li * OCS-dependent * Asthma exacerbation in the 4 weeks preceding the study visit * Concomitant disease, health condition, and/or lifestyle activities that could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease. These include, but are not restricted to: heart failure, previous bipolar decompensation with prednisone, severe blood hypertension, uncontrolled diabetes, pneumonia. * Unwilling or unable to comply with the study protocol for any other reason

Inclusion Criteria: 1. Signed written informed consent 2. ≥18 years of age 3. Histologically or cytologically confirmed HER2 negative breast cancer for whom IV paclitaxel monotherapy has been recommended. 4. HER2 negative per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guideline. Subjects can be estrogen receptor/progesterone receptor (ER/PR) positive or negative per ASCO CAP guideline, but ER/PR and HER2 receptor status must be known. 5. Metastatic breast cancer with target lesions measurable by CT scan per RECIST v1.1 criteria confirmed by BICR 6. Adequate hematologic status as demonstrated by not requiring granulocyte colony stimulating factor (G CSF) or transfusion support within 30 days prior to randomization to achieve the following at screening: * Absolute neutrophil count (ANC) ≥1500/mm3 * Platelet count ≥100,000/mm3 * Hemoglobin ≥9 g/dL 7. Adequate liver function as demonstrated by: * Total bilirubin ≤upper limit of normal (ULN) unless the subject has Gilbert's disease, for which bilirubin must be ≤2.0 × ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 × ULN 8. Adequate renal function as demonstrated by estimated glomerular filtration rate (eGFR) ≥60 mL/min 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 10. Life expectancy at least 6 months, in the judgment of the Investigator 11. Female subjects must be postmenopausal (≥12 months without menses) or surgically sterile (ie, by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or must be using effective contraception (ie, non-hormonal intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment. 12. Women of childbearing potential must have a negative screening serum pregnancy test and urine test within 4 days prior to start of dosing in the study and not be breast feeding. 13. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of investigational product (IP). Exclusion Criteria: 1. Not recovered to ≤grade 1 toxicity from previous anticancer treatments or previous investigational product (IP) except alopecia 2. QTcF interval ≥470 msec at baseline 3. Relapsed less than 6 months following treatment with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease 4. Known active central nervous system metastasis, including leptomeningeal involvement 5. Currently receiving other medications intended for the treatment of their malignancy 6. Received other IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer 7. Received biologics or monoclonal antibodies intended for the treatment of their malignancy within 30 days of the first study dosing day 8. Received radiation therapy within 2 weeks prior to signing informed consent or radiation therapy is planned within 6 months from the time of signing informed consent 9. Taking a medication known to be a moderate or strong cytochrome P450 (CYP) 3A4 inhibitor or inducer or neurokinin-1 receptor antagonist (NK-1) inhibitor within 14 days prior to start of dosing in the study 10. Taking a medication known to be a moderate or strong CYP2C8 inhibitor or inducer within 14 days prior to start of dosing in the study 11. Taking an oral medication with a narrow therapeutic index known to be a P-glycoprotein (P-gp) substrate within 24 hours prior to start of dosing in the study 12. Taking a medication known to be a P-gp inhibitor or inducer within 14 days prior to start of dosing in the study 13. Taking a medication known to be an organic anion transporting polypeptide 1B1/3 (OATP1B1/3) inhibitor 14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements 15. Major surgery to the upper GI tract, inability to take oral medication, or have a history of GI disease or other medical condition that, in the opinion of the Investigator may interfere with oral drug absorption 16. History of significant hypersensitivity-type reaction to paclitaxel or Cremophor EL that would contraindicate the use of IV paclitaxel 17. Known allergic reaction or intolerance to contrast media 18. Documented history of true systemic allergic reaction to 3 or more medications 19. Active hepatitis B (as evidenced by being HBsAg positive) or active hepatitis C (HCV-RNA positive) or cirrhosis of the liver 20. Known HIV infection 21. The Investigator believes that participation in this study would not be acceptable

3.1 Inclusion Criteria Subjects must meet all of the following criteria to be eligible: Age and gender: Female, ≥18 years old. Histopathological confirmation: Invasive breast cancer confirmed by histopathology. No prior systemic anti-tumor therapy for breast cancer. Triple-negative PD-L1-positive breast cancer: ER/PR-negative (IHC nuclear staining \<10%). HER2-negative (IHC 0/1+ without FISH testing or IHC 2+ with FISH-negative amplification). PD-L1 Combined Positive Score (CPS) ≥1. Tumor stage: T1c-T2, N0-1 or T1a-T1b, N1 (per AJCC 8th Edition criteria). Measurable lesion: At least one measurable target lesion per RECIST v1.1. ECOG performance status: 0-1. Life expectancy: ≥3 months. Adequate organ and bone marrow function (within 1 month prior to treatment, without corrective therapy within 14 days before first dose): Bone marrow: Absolute neutrophil count (ANC) ≥2.0 ×10\^9/L. Platelets ≥100 ×10\^9/L. Hemoglobin ≥100 g/L. Liver/kidney function: Albumin ≥3.0 g/dL. Total bilirubin \<1.5 × ULN. ALT/AST \<1.5 × ULN. Alkaline phosphatase ≤2.5 × ULN. BUN and serum creatinine \<1.5 × ULN or creatinine clearance \>60 mL/min (Cockcroft-Gault formula). Coagulation: PT and APTT ≤1.5 × ULN. Cardiac function: LVEF ≥55% by echocardiography (ECHO). QT interval: QTcF ≤470 ms. Reproductive status: Premenopausal women: Negative serum pregnancy test within 14 days before treatment. Non-lactating. All subjects must use effective barrier contraception during treatment and for 6 months post-treatment. Informed consent: Willing to sign informed consent and comply with study procedures. 3.2 Exclusion Criteria Subjects meeting any of the following criteria will be excluded: Unconfirmed diagnosis: Breast cancer not histopathologically confirmed. Specific subtypes: Bilateral, inflammatory, or occult breast cancer. Metastatic disease: Evidence of metastatic breast cancer (excluded via chest/abdominal CT and bone scan; PET/CT allowed as alternative). Prior anti-tumor therapy: Chemotherapy, radiotherapy, targeted therapy, or endocrine therapy for breast cancer. Curative radiotherapy within 4 weeks or palliative radiotherapy within 2 weeks before first dose. Prior immunotherapy: Anti-PD-1, anti-PD-L1, anti-PD-L2, or other immune checkpoint inhibitors. Concurrent anti-tumor therapy: Any other anti-cancer treatments during the study. Second primary malignancy: Except adequately treated non-melanoma skin cancer. Transplant history: Prior organ or bone marrow transplantation. Recent clinical trials: Participation in another drug trial within 4 weeks prior to enrollment. Immunosuppressive therapy: Systemic corticosteroids (\>10 mg/day prednisone equivalent) or immunosuppressants within 2 weeks before first dose (excluding inhaled/topical steroids). Vaccination: Live or attenuated vaccines within 4 weeks before first dose. Major surgery: Non-breast-related major surgery within 4 weeks before first dose or incomplete recovery. Autoimmune diseases: Active autoimmune disease or history of autoimmune disease with potential recurrence (e.g., autoimmune hepatitis, uveitis, thyroid dysfunction requiring systemic treatment). Exceptions: Vitiligo, psoriasis, alopecia, controlled childhood asthma, or type 1 diabetes managed with insulin. Immunodeficiency: HIV-positive, congenital/acquired immunodeficiency disorders. Cardiovascular disease: History within 6 months: Myocardial infarction, stroke (excluding lacunar infarct), pulmonary embolism, unstable angina, NYHA Class III/IV heart failure. Clinically significant arrhythmia, primary cardiomyopathy, atrial fibrillation (EHRA ≥2b), uncontrolled hypertension, or QTcF \>470 ms. Pulmonary disease: Interstitial lung disease, idiopathic pulmonary fibrosis, severe COPD/asthma, or autoimmune/collagen vascular diseases with pulmonary involvement. Infections: Active hepatitis B (HBsAg+ with HBV DNA ≥500 IU/mL), hepatitis C (HCV RNA \> ULN), cirrhosis, or severe infections requiring antimicrobial therapy. Bleeding/thrombosis disorders: Hereditary/acquired bleeding or thrombotic tendencies (e.g., hemophilia). Hypersensitivity: Allergy or contraindication to study drug components. Pregnancy/lactation: Pregnant, breastfeeding, or unwilling to use contraception. Comorbidities: Uncontrolled conditions (e.g., hypertension, diabetes, active infections) contraindicating ADC or PD-L1 inhibitors. Neurological/psychiatric disorders: Epilepsy, dementia, or other conditions deemed unsuitable by the investigator.

Inclusion Criteria: * 18 years of age or older * Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications * Written informed consent signed from subject prior to performing any protocol-related procedures Exclusion Criteria: * Use of any investigational agent within 14 days prior first visit; * Patient under guardianship/trusteeship or legally incapacitated person; * Patient unable to understand read and/or sign an informed consent; * Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties; * Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme; * Patients who are known to be HIV positive